fouremm - Although I wholeheartedly agree with your funding and other comments from a historical point of view, at this point of this BoM trial which has CKD effects as a pre stated secondary end point, raising additional funds to start and complete this CKD trial could be unnecessary dilution. In order to have sites go through legal requirements, recruit, complete dosing and have the data analyzed and disseminated, the top line and maybe the full data set for BoM could be out. There will be 104 full weeks of data for CKD patients in the BoM trial versus 8 weeks in the planned CKD crossover trial. Look at the amount of time it took to get the full data set from the first CKD trial done in New Zealand from start to finish. There is no question that things could have been done much differently in the past. Right now, in my mind, the best use of capital is to complete the BETonMACE trial. If another company wants to step up to the plate and put money up for this CKD trial then by all means.

tada